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Abstract
Silymarin, an extract from milk thistle (Silybum marianum), and its purified flavonolignans have
been recently shown to inhibit HCV infection, both in vitro and in vivo. In the current study, we
further characterized silymarin's antiviral actions. Silymarin had antiviral effects against HCVcc
infection that included inhibition of virus entry, RNA and protein expression, and infectious virus
production. Silymarin did not block HCVcc binding to cells, but inhibited the entry of several viral
pseudoparticles (pp), and fusion of HCVpp with liposomes. Silymarin but not silibinin inhibited
JFH-1 genotype 2a NS5B-dependent RNA polymerase activity at concentrations 5–10 times
higher than required for anti-HCVcc effects. Furthermore, silymarin had inefficient activity on the
genotype 1b BK and four 1b RDRPs derived from HCV-infected patients. Moreover, silymarin
did not inhibit HCV replication in 5 independent genotype 1a, 1b, and 2a replicon cell lines that
did not produce infectious virus. Silymarin inhibited microsomal triglyceride transfer protein
activity, apolipoprotein B secretion, and infectious virion production into culture supernatants.
Silymarin also blocked cell-to-cell spread of virus. While inhibition of in-vitro NS5B polymerase
activity is demonstrable, the mechanisms of silymarin's antiviral action appear to include blocking
of virus entry and transmission, possibly by targeting the host cell.
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Chronic hepatitis C is a serious global medical problem necessitating novel, effective,
inexpensive, and less toxic treatments. Hepatitis C virus (HCV), infects an estimated 130
million people throughout the world, leading to a half million deaths per year due to liver
disease (1).
Pegylated interferon (IFN) plus ribavirin therapy is the current treatment for the patient with
chronic hepatitis C (2). However, 50% of treated patients do not clear viremia during
treatment, which is costly and has significant side effects. As a result, many patients use
natural products to supplement or circumvent IFN-based regimens, with silymarin being the
most common botanical medicine (3).
Silymarin is an extract from the of Silybum marianum, that consists of at least seven
flavonolignans and the flavonoid taxifolin (4). Silibinin is a partially purified mixture of two
of flavonolignans, silybin A and silybin B. Silymarin has been used to treat a range of liver
disorders including hepatitis, cirrhosis, and poisoning from wild mushrooms (5). Recently,
we showed silymarin inhibits HCV infection of Huh7 and Huh7.5.1 cells (6), and Ferenci's
group showed that intravenous silibinin administration reduces viral loads in previous non-
responders to IFN therapy (7). Therefore, in the current study, we determined the stages in
the HCV lifecycle that are blocked by silymarin.
Experimental Procedures
Reagents
Human hepatoma Huh7 cells were grown in Huh7 medium as described (6). HepG2 cells
and Huh7.5.1 cells (8) were cultured in Huh7 medium. BB7 and FL-NEO cells are Huh7
cell lines that contain subgenomic and genomic length genotype 1b replicons(9). JFH-1
subgenomic genotype 2a replicon cell lines in Huh7 or Huh7.5 backgrounds were generated
by transfecting in-vitro transcribed SGR-JFH1 replicon RNA into Huh7 or Huh7.5 and
selecting with 800 μg/mL G418. Single colonies expressing the highest level of HCV
protein were designated SGR7 and SGR7.5. Luc-ubi-neo/ET is a subgenomic genotype 1b
derived replicon cell line (10). The HCV genotype 1a H77s subgenomic replicon cell line
has been described previously (11). All replicon lines were maintained in Huh7 medium
containing 400 μg/ml G418. Primary human hepatocytes were kindly provided by Dr.
Stephen Strom, University of Pittsburgh and maintained in hepatocyte culture medium
(Lonza, Walkersville, MD).
JFH-1 viral stock preparation, cell infection and titration was performed as described (6).
Silymarin from US Pharmacopeia (Rockville, MD) was used in all experiments except for
the MTP (figure 4A) and apoB (Figure 4E) assays, where silymarin from Sigma. Sigma
silymarin contains similar levels of the major flavonolignans as USP silymarin, as described
in (12). Stocks were prepared in DMSO at a concentration of 50 mg/ml. Silibinin was
purified from silymarin as described (13).
Egg yolk phosphatidylcholine (PC), cholesterol and Triton X-100 were purchased from
Sigma. Octadecyl rhodamine B chloride (R18) was from Fluoprobes.
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Addition of compounds to cultures
Silymarin was further diluted in DMSO prior to use and the final concentration of DMSO in
culture media was always between 0.2–0.4%. Silymarin treatment involved exposing cells to
a single administration of silymarin for various times. DMSO was included as a solvent
control. To focus on the effects of silymarin on infectious virus production, cells were first
infected at a m.o.i. of 0.01 and cells were passaged at 72 hours post-infection, followed by
addition of silymarin 24 hours after passaging, or 96 hours post-infection. Under these
conditions, the culture was fully infected (Supplemental Figure S1).
Roferon, Intron-A, or Pegasys was used as positive controls for antiviral effects. Roferon
(Roche, Pal Alto, CA) was used at 10 IU/ml, Pegasys was used at 10 ng/ml, and Intron-A
was used at various concentrations. BMS-200150, a small molecule inhibitor of MTP, was
provided by Pablo Gastaminza and Francis Chisari.
Western Blot Analysis
Western blots were performed as described (6). GAPDH, apoB, Stat1, NS5A in FL-NEO
and BB7 cells, and core proteins were detected using commercial antiserum (Santa Cruz
Biotechnology, Santa Cruz, CA; BioDesign/Meridian Life Science, Saco, ME; Affinity
BioReagents, Golden, CO). NS5A in JFH-1 infected cells was detected with serum from
patients infected with HCV genotype 2a.
HCV RNA Quantitation
HCV RNA was quantitated by real time RT-PCR, as previously described (14).
HCV luciferase replicon assay
Luc-ubi-neo cells were plated and grown for 24 hours. Medium was removed, the cells
washed once and treated subsequently with given concentrations of silymarin or DMSO in
triplicate. After 3 days of incubation at 37°C, cell culture medium was removed and cells
were lysed by freeze-thawing in buffer and luciferase assays were performed.
HCV-1a Replicon Assay
Antiviral studies to determine the impact of silymarin treatment on HCV RNA levels with
the genotype 1a replicon were conducted using real time RT-PCR and assay conditions
previously described (15).
HCV NS5B Polymerase Assays
NS5BΔC21 C-terminally fused to a hexa-histidine tag was expressed and purified for HCV
JFH1 and for the genotype 1b isolates as described (16,17). All reaction components except
nucleotides and template were preincubated for 15 minutes at room temperature, then the
reaction was started by adding the nucleotide mixture and template and was incubated for
1.5 hours at room temperature. Reaction products were precipitated, passed through filters,
washed five times, and air dried. Samples were subjected to liquid scintillation counting. All
measurements were done in triplicate and the IC50 values were calculated with GraphPad
Prism.
Viral Pseudoparticle Entry Assays
Pseudoviruses were generated as previously described (18). Huh-7.5 cells were pretreated
for 1hr with 40, 80 and 160 μM silymarin (SM) or equivalent volume of DMSO, diluted in
media. Cells were inoculated with an equal volume of pseudoparticles bringing the final
concentration of SM to 20, 40 and 80 μM. 72 h post-infection, the medium was removed and
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cells lysed with cell lysis buffer (Promega, Madison, WI). Luciferase activity was then
measured. Specific infectivity was calculated by subtracting the mean Env-pp signal from
the HCVpp, MLVpp or VSVpp signals. Relative infectivity was then calculated as a
percentage of untreated control cell infection, i.e. the mean luciferase value of the replicate
untreated cells was defined as 100%.
Fusion assay
Fusion between HCVpp and liposomes was assayed as already described (19). Briefly,
liposomes composed of PC, cholesterol and Octadecyl Rhodamine B chloride (R18) (65:30:5
mol%) were added at a 15 μM final concentration to a cuvette at 37°C containing HCVpp in
PBS at pH 7.2. After equilibration, diluted HCl was added to pH 5.0 final and lipid mixing
measured as the dequenching of R18 (excitation 560 nm, emission 590 nm), resulting in an
increase in the fluorescence signal. Silymarin was preincubated with HCVpp and liposomes
for 3 min at 37°C, and lipid mixing measured after medium acidification.
Infectious Virion Production
Culture supernatants were harvested at defined times points post-infection, and supernatants
were clarified by centrifugation. Intracellular virus titers were determined after treatment
with Brefeldin A (BFA), which has been shown to block HCV release by causing
intracellular accumulation of virions. For this, treated cells were scraped into PBS and lysed
by freeze-thawing as described (20). All supernatants were stored at −80C before dilution
and titering on naïve Huh7.5.1 cells using standard focus-forming unit (FFU) assays as
previously described (8).
Cell to Cell Spread
Cell to cell spread of virus was measured as previously described (21). Briefly, unlabelled
naive `target' cells were incubated with HCV H77/JFH infected `producer' cells that were
labeled with CMFDA (Molecular Probes, Invitrogen, Carlsbad, CA). A neutralizing
antibody was added to the co-culture to abrogate the infectivity and transmission of cell-free
virus particles within the culture media, allowing us to quantify antibody insensitive viral
transmission. Infection was quantified by staining the co-cultures with an anti-NS5A
antibody (9E10) and appropriate secondary antibody, followed by flow cytometry.
apoB ELISA
Huh7.5.1 cells were grown overnight in Huh7 media. The media was removed and cells
were washed, and fresh medium with the appropriate compounds was added to cells. Culture
supernatants were harvested at 24 and 48 hours later, clarified by centrifugation and stored
at −80°C. apoB was measured by ELISA using manufacturer's protocol (ALerCHEK,
Portland, ME).
MTP Assay
MTP activity was measured using a commercially available fluorescence assay using a
commercial kit (Roar Biomedical, Inc., New York, NY) as described (22)
Statistics
Differences between means of readings were compared using a Student's T-test. A p-value
of <0.05 was considered significant.
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Results
We previously showed that silymarin inhibits HCV RNA and protein expression in the
HCVcc system with JFH-1 virus (6). Figure 1A demonstrates that in addition to wild type
JFH-1 virus, silymarin also blocks replication of HCVcc chimeras, including constructs that
contain the H77 (genotype 1a) and J6 (genotype 2a) structural genes in the JFH-1 non-
structural gene backbone. Inhibition of HCVcc was 50% for H77/JFH and 75% for J6/JFH
chimeras. Thus, silymarin has antiviral actions against multiple HCVcc infectious systems.
To determine if silymarin could inhibit binding of HCV virions to cells, we performed virus-
cell binding studies at 4°C under conditions where virus binds to but does not enter cells
(23). As shown in Figure 1B, when silymarin was present only during virus-binding, there
was little effect on HCV replication. However, if silymarin was added to cells immediately
after binding and for the duration of the infection, HCV protein expression was severely
impaired. The same effect was observed if silymarin was present during binding and for the
duration of the experiment. Next, to determine if silymarin blocked virus entry, we tested the
effect of silymarin on viral pseudoparticle entry including HCVpp, VSVpp, and MLVpp.
Figure 1C demonstrates that silymarin inhibited the entry of all three pseudotyped viruses.
We then examined the effect of silymarin on the fusion of HCVpp with fluorescent
liposomes, which examines the effects of compounds on lipid mixing and membrane fusion
(24). As shown in Figure 1D, silymarin drastically inhibited HCVpp-mediated fusion by
80% at 10 μM silymarin, while 20 μM led to a 90% reduction in fusion. DMSO, the solvent
control, did not affect fusion. The IC50 of silymarin for membrane fusion inhibition was
estimated at 5 μM, far below the doses of silymarin known to confer cytotoxicity in
Huh7.5.1 cells (>80 μM, Supplemental Figure S2, Panel E). The data suggest that silymarin
does not affect binding, but inhibits the entry of HCV at the fusion stage.
Next, we examined the kinetics of inhibition of HCV RNA production. In this experiment
we first infected cells for 24 hours, followed by silymarin administration, or IFN-α as a
positive control. As shown in Figure 1E, relative to untreated cells, silymarin caused a
significant (p<0.01) reduction in JFH-1 RNA production at 48 and 72 hours after treatment.
IFN treatment also reduced viral loads. However, significant suppression (p<0.01) of HCV
RNA production by IFN started at 18 hours post-treatment and was maintained until 72
hours of treatment. Thus, the kinetics of silymarin mediated suppression of HCV RNA
replication were delayed as compared to IFN.
As shown in Figure 1F, silymarin reduced infectious virus yields (measured as FFU/ml) by
5- and 2-fold at 48 and 72 hours post-infection from Huh7.5.1 cells (and in Huh7 cells; data
not shown). We can rule out the possibility of carry over silymarin from the initial culture
because the supernatants were diluted 1:5–1:1000 before testing on naïve cells. Altogether,
the data show that silymarin does not affect virus binding to cells, but inhibits virus entry
and fusion, HCV protein and RNA synthesis, and production of progeny viruses in culture
supernatants.
Inhibition of HCV RNA and protein expression by silymarin could be due to direct
inhibition of viral enzymes, as recently shown for NS5B polymerase activity (25).
Therefore, we tested whether silymarin and silibinin block HCV NS5B polymerase activity.
Recombinant NS5B protein from JFH-1 (genotype 2a) lacking the C-terminal 21 amino
acids was expressed in E. coli and purified (16). As shown in Figure 2, silymarin was able to
inhibit JFH-1 NS5B polymerase activity, with an IC50 for silymarin around 300 μM.
Silibinin had minimal effects on JFH-1 polymerase, but only at very high doses (IC50
>400μM), which were at least 5–10 fold higher than effective antiviral doses in vitro (6). At
the doses required for inhibition of in-vitro NS5B polymerase activity, silymarin is toxic to
cultured Huh7 (6) and Huh7.5.1 cells (Supplemental Figure S2).
Wagoner et al. Page 5
Hepatology. Author manuscript; available in PMC 2011 June 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
We next tested silymarin on RdRp activity of the genotype 1b BK strain and four patient-
derived 1b RdRps from patients in the Virahep-C clinical study (26). The RNA polymerase
activities of the patient-derived enzymes were variable (16–104% relative to the well-
characterized BK enzyme; Table 1). Silymarin inhibited all five RdRps, with IC50 values
ranging from 27.7 to 162 μM. However, in four of the five cases the inhibitory activity of
silymarin rapidly plateaued, with maximal inhibition levels of 42.6 to 82.8% relative to the
activity in the absence of silymarin (Supplemental Figure S3). The fifth enzyme (#242) had
an inhibition profile that could not be fit to a single-phase exponential decay curve, but its
maximal inhibition by silymarin was only 43% and its apparent IC50 was >1,000 μM.
Therefore, the IC50 values for most of these subtype 1b RdRps were respectable below the
plateau level, but they were poorly inhibited by silymarin at the concentrations employed in
the cell culture experiments.
If silymarin truly inhibits NS5B polymerase activity, it should be able to inhibit HCV
replication in replicon cell lines that do not produce infectious virus. Figure 3A–C depicts
the effects of various doses of silymarin on HCV protein and RNA expression in genotype
1b BB7 subgenomic and FL-NEO genomic replicon cell lines. Silymarin did not
significantly inhibit viral protein expression in either cell line when assessed by western blot
(Figure 3A) or by immunofluorescence (Figure 3B). Silymarin did not inhibit HCV RNA
expression in either cell line(Figure 3C). HCV replication was also not inhibited by
silymarin in Luc-ubi-neo/ET cells, an independent genotype 1b replicon. (Figure 3D), or in a
subgenomic genotype 1a replicon cell line (Figure 3E). In contrast, treatment with IFN-α
caused robust suppression of HCV RNA production from the HCV-1a replicon. We tested
concentrations of silymarin up to 1000 μM but failed to see any suppression of HCV RNA
from the 1a replicon that was independent of cytotoxicity, measured as GAPDH mRNA
levels (Supplemental Figure S4). NS5A protein expression was not affected by silymarin in
JFH-1 derived genotype 2a SGR7 (Figure 3F) or SGR7.5 replicon cell lines (data not
shown). Furthermore, extended treatment of FL-NEO replicon cells (or BB7 cells; data not
shown) for 13 days did not affect the levels of HCV NS5A protein (Supplemental Figure
S5). Therefore, silymarin had no antiviral activity against replicon cell lines that did not
produce infectious virus. The data in Figures 2 and 3 suggest that silymarin inhibition of
NS5B polymerase activity is not a significant component of silymarin's anti-HCV activity in
the HCVcc system.
HCV assembles at lipid droplets (27,28), and the virus is thought to exit the infected liver
cell by hitching a ride on the apolipoprotein assembly and secretion pathway, in particular
MTP-dependent VLDL release (20,29,30). Because silymarin blocked infectious virus
production (Figure 1), we determined whether silymarin also inhibits MTP activity and
apoB secretion. In these studies, silymarin was added to cells that were either fully infected
(96 hours post-infection) or chronically infected for 14 days. Thus, the experimental design
effectively eliminated antiviral effects involving blockade of virus entry and instead allowed
us focus on the effects of silymarin on production of progeny viruses. Silymarin inhibited
MTP activity in a dose-dependent manner in 14-day chronically infected cells by 25±15%
and in non-infected cells by 66±1% at 80 μM (Figure 4A). Naringenin, shown recently to
block MTP-dependent virus release (22), also blocked MTP activity. Silymarin inhibition of
MTP activity correlated with reduced apoB secretion in both mock and JFH-1 infected
Huh7.5.1 cells (Figure 4B). The small molecule inhibitor of MTP, BMS-200150, served as a
positive control for inhibition of apoB secretion. Silymarin inhibition of MTP activity and
apoB secretion correlated with a reduction in de novo virion production from fully infected
cultures treated for 5 hours (Figure 4C). Importantly, the reduction in infectious virus
production was not due to a reduction in intracellular replication, as NS5A protein levels
were not affected by the 5-hour treatments with DMSO, silymarin, or BMS-200150 (Figure
4D). Furthermore, the effect on apoB secretion was not unique to Huh7 cells as silymarin
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also caused dose-dependent suppression of apoB secretion from primary human hepatocytes
(Figure 4E) and HepG2 cells, as measured by ELISA and western blot (Figure 4F). When
we examined intracellular infectious virus as a measure of virus assembly, the general
secretion inhibitor Brefeldin A (BFA) caused accumulation of intracellular infectious virus,
which was inhibited by the MTP inhibitor BMS-200150, as described (20). However,
silymarin had no effect on BFA-induced accumulation of infectious virus (Supplemental
Figure S6). Collectively, the data demonstrate that silymarin blocks MTP-dependent apoB
secretion and infectious virion production into culture supernatants, but does not appear to
block virus assembly. We then determined if silymarin blocks other pathways of virus
transmission.
It has been recently shown that in addition to releasing virus particles into culture medium,
HCV is capable of direct cell-to-cell transmission (21). To examine effects of silymarin on
this antibody insensitive route of transmission, we used a novel assay where fluorescently
labeled infected producer cells were mixed with unlabeled naïve cells and HCV NS5A
protein expression was detected using antibodies labeled in the red spectrum. Silymarin
reduced both total and cell-to-cell transmission (Figure 5A). We also observed equal
suppression of both total and cell-to-cell transmission (Figure 5B), suggesting that silymarin
does not discriminate between routes of virus transmission.
Discussion
Despite global use for millenia, the detailed molecular mechanisms of silymarin-induced
hepatoprotection are not known. In recent studies (6,31) we have shown that silymarin
displays antiviral, anti-inflammatory, and immunomodulatory functions. These activities,
together with antioxidant functions of silymarin (32) could effectively comprise the
hepatoprotection observed in many animal models of liver disease (33–35). Using HCVpp,
HCVcc, and liposome mixing experiments, we demonstrate that silymarin inhibits virus
entry and fusion, RNA and protein synthesis, and infectious virus production into culture
supernatants and cell-to-cell spread. Silymarin but not silibinin inhibited NS5B polymerase
activity. The lack of activity of silibinin in our study contrasts with a recent study showing
silybin A, silybin B, and their water-soluble dihydrogen succinate forms found in Legalon-
SIL, a commercial preparation of silibinin, inhibited HCV polymerase function, with IC50s
in the 75–100 μM range(25). The water soluble versions of silybin A and silybin B found in
Legalon-SIL contain two succinate moieties that increase the molecular weight of the
compound by over 244 atomic mass units, from 482 to 726. Thus, the water soluble
molecules are quite different chemically from the natural compounds, which are insoluble in
water, and as a result the metabolism and biological effects of the compounds may differ.
However, in our study, silymarin did not inhibit HCV RNA and protein expression in
multiple independent replicon cell lines that did not produce infectious progeny viruses; in
agreement with a recent study showing that silymarin did not inhibit HCV NS5A protein or
RNA expression in a subgenomic replicon cell line(36). The data suggest that blockade of
polymerase activity is not a major antiviral mechanism, at least in the HCVcc system.
Instead, we provided evidence to suggest that inhibition virus entry and virus transmission
contribute to the antiviral effects of silymarin.
Indeed, silymarin blocked the entry of three different enveloped pseudoviruses, and also
potently inhibited the fusion of liposome membranes. Silymarin flavonolignans belong to
the family of phytoestrogens and are composed of a phenylbenzopyrone structure (4). The
structures of these molecules are relatively hydrophobic, so it is possible that silymarin may
act by incorporating into lipid membranes of both viruses and target cells, or at least may
display partition into lipid bilayers, similar to other plant flavonoids (37). This would lead to
the stabilization of membranes by silymarin, which would in turn become less prone to
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fusion. This behaviour is reminiscent of arbidol, a broad-spectrum antiviral inhibiting HCV
entry, membrane fusion and replication (24). This hypothesis is further corroborated by our
observations that silymarin blocks cell entry of pseudotyped particles of other enveloped
viruses such as VSVpp and MLVpp. Future studies will focus on further dissecting these
mechanisms.
We also showed that silymarin inhibits MTP activity, apoB secretion, and production of
infectious virus particles. In support of this argument and in agreement with the results
obtained in the current report, the flavonoid taxifolin which is present in silymarin, has been
shown to block MTP activity and apoB secretion (38). Silymarin has also been shown to
alter lipid profiles (39), so it is possible that the botanical may block virus transmission by
targeting multiple components of lipid metabolism.
Silymarin does many things to cells including modulation of signal transduction (40), the
redox state (41), T-cell function (6,31), and NF-κB (42). These studies suggest that direct
effects of silymarin on cell functions is responsible for the prevention of liver disease in
many animal models (33–35). We therefore hypothesize that silymarin's blockade of virus
entry and transmission occurs by targeting the host cell. Studies are in progress to identify
the cellular target(s) of silymarin that may explain the many activities elicited by this
botanical.
Our demonstration of anti-HCV actions of silymarin (6) was initially at odds with clinical
studies that found no effect of silymarin on HCV replication in vivo (43). However, daily
intravenous administration of a soluble form of silibinin inhibits HCV viral loads by 3–4
logs in 1–2 weeks in previous IFN non-responder patients (7). This important study
illustrates the clear differences in outcome based on route of administration and the type of
silymarin-derived preparation being tested. Further clinical and in vitro studies are required
to evaluate silymarin's hepatoprotective effects, metabolism and bioavailability. Moreover,
since it is now clear that patients with chronic hepatitis C self-prescribe botanicals,
especially silymarin (3), regardless of whether they receive standard of care therapy with
pegylated IFN plus ribavirin, it will be important to design clinical trials that evaluate the
effects and interactions of silymarin, given orally and intravenously, either by itself or with
antivirals for HCV, including new STAT-C therapies, on reduction of viral load and
improvement in liver function and/or prevention of liver disease. Because of its multiple
actions on cells and hypothesized modulation of cellular targets, silymarin and silymarin-
derived compounds may also prove relevant for liver diseases of non-viral origin.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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List of Abbreviations
apoB apolipoprotein B
BFA Brefeldin A
CAM complementary and alternative medicine
CMFDA 5-chloromethylfluorescein diacetate
HCV hepatitis C virus
HCVcc hepatitis C virus cell culture
HCVpp hepatitis C virus pseudoparticle
IFN interferon
MTP microsomal triglyceride transfer protein
m.o.i. multiplicity of infection
NS non-structural
RdRp RNA dependent RNA polymerase
RT-PCR reverse transcriptase polymerase chain reaction
SB silibinin
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis
SGR subgenomic replicon
SM silymarin
TNF-α tumor necrosis factor alpha
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Figure 1. Antiviral effects of silymarin against HCVcc
A, Silymarin inhibits virus infection in multiple HCVcc systems. Huh-7.5 cells were
incubated with 80μM silymarin or DMSO for 1hr at 37C before inoculation with either H77/
JFH or J6/JFH HCVcc viruses. The infection was allowed to proceed in the presence of the
compounds for 48 and 72hrs before virus was quantitated by staining for NS5A-positive
foci. Percent inhibition reflects inhibition of NS5A-positive foci by silymarin relative to the
DMSO control. B, Silymarin does not block virus binding. Huh7.5.1 cells were incubated at
4°C for 5 hours in the presence of HCVcc (JFH-1, m.o.i. of 0.01) with or without 40μM
silymarin. Cells were then washed extensively at 4°C and then cells were incubated for 72
hours at 37°C to allow the HCV lifecycle to continue in the presence or absence of
additional silymarin. “M” denotes mock infected cells. “0” denotes cells that were infected
but not treated with anything. “Binding @ 4C” denotes silymarin was only present during
the 5-hour adsorption period. “Post-binding” denotes silymarin was added after the 5-hour
adsorption period and for the duration of the infection. “Normal” denotes silymarin was
present during the 5-hour adsorption and for the duration of the infection. C, Silymarin
inhibits pseudoparticle entry. Huh-7.5 cells were treated with silymarin (SM) or equivalent
volume of DMSO for 1 hour prior to infection with HCV, VSV, or MLV pseudoparticles
(pp). 72 h post-infection, the medium was removed and luciferase activity was measured on
cell lysates. D, Silymarin blocks HCVpp-mediated lipid mixing. HCVpp in PBS at pH 7.2
were incubated or not with indicated concentrations of silymarin in DMSO, for 3 min at
37°C, in the presence of PC:cholesterol:R18 liposomes. Acidification to pH 5.0 was
performed by adding diluted HCl to the cuvette, and R18 dequenching was assayed for 15
min at excitation and emission wavelengths of 560 and 590 nm, respectively. Maximal
dequenching was obtained after addition of 0.1% final Triton X-100 to the cuvette. Black,
no silymarin; blue, 10 μM; green, 20 μM and red, 80 μM silymarin, respectively. Dotted
curve, lipid mixing in the presence of 1% final DMSO (highest concentration used in the
assay). E, Silymarin inhibits HCV RNA production. Huh7.5.1 cells were infected at an
m.o.i. of 0.01 with JFH-1 and 24 hours later, silymarin (40μM) or IFN (10 units/ml) was
added to cells, and thereafter, total RNA was isolated from cells at the indicated time points.
HCV RNA was quantitated by real time RT-PCR. Asterisks indicate silymarin or IFN
reduction of viral loads is significantly different than untreated cells (p<0.01). F, Silymarin
reduces infectious virus production into culture supernatants. Huh7.5.1 cells were infected at
an m.o.i. of 0.01 with JFH-1 in the presence of 40μM silymarin or DMSO and supernatants
were harvested 48 and 72 hours post-infection and titered by FFU assay on naïve Huh7.5.1
cells.
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Figure 2. Silymarin inhibits JFH-1 polymerase at high dose
HCV NS5B polymerase from isolate JFH-1 (genotype 2a) was incubated with the indicated
concentrations of Silymarin or Silibinin, respectively, in presence of [32P]GTP and polyC.
Incorporation of radioactivity was quantified by TCA precipitation and liquid scintillation
counting. Silymarin and to a lesser degree, silibinin, inhibited JFH-1 polymerase.
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Figure 3. Silymarin does not block HCV replication in HCV replicon cell lines
Cells were treated once with the indicated doses of silymarin and incubated for 72 hours
before replication was assessed. A, protein expression in subgenomic BB7 and genomic FL-
NEO HCV-1b replicons following treatment with 20–80 μM of silymarin. D=DMSO.
Positions of HCV NS5A and cellular Stat1 proteins are indicated. B, Intracellular NS5A
protein expression in DMSO and silymarin treated FL-NEO cells. Cells were treated as
described above and NS5A protein detected by immunofluorescence as described in the
Materials and Methods. NS5A positive cells are depicted in green while the blue cells
represent nuclei counterstained by DAPI. C, HCV RNA levels in FL-NEO and BB7 cells. D,
Effect of silymarin against Luc-ubi-neo/ET cells, a Con1-based genotype 1b replicon
subgenomic replicon. Values represent percent change in luciferase light units relative to
DMSO control. E, Effect on HCV-1a subgenomic replicon. Left panel shows HCV and
GAPDH RNA levels following Silymarin treatment, while right panel shows RNA levels
following treatment with Intron-A (recombinant IFN-α). F, Effect of silymarin on
subgenomic genotype 2a JFH-1-derived Huh7 replicon cell line. Cells were treated with 20
or 40μM of silymarin. Positions of HCV NS5A and cellular GAPDH proteins are indicated.
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Figure 4. Silymarin inhibits microsomal triglyceride transfer protein (MTP) activity,
apolipoprotein B (apoB) secretion, and infectious virus production
A, Silymarin inhibits MTP activity in Huh7.5.1 cells. Chronically infected Huh7.5.1 cells
(14 days post-infection) and uninfected cells were treated with the indicated μM doses of
silymarin (SM) or as a positive control, 200 μg/ml naringenin (NN), and 24 hours later MTP
activity was measured as described in the Materials and Methods. B, Silymarin inhibits
apoB secretion from mock and HCV-infected cells. Huh7.5.1 cells were infected or mock-
infected with JFH-1 at an m.o.i. of 0.01 for 96 hours before treatment with fresh medium
containing DMSO, 10μM BMS-200150 (a small molecule inhibitor of MTP), or silymarin at
the indicated μM doses for 5 hours. Culture supernatants were harvested, and apoB
measured by ELISA. BMS=BMS-200150. C, De novo infectious virion production into
culture supernatants is blocked by silymarin. Supernatants from panel B were diluted 1:20
and infectious titers were determined by focus forming unit assay on naïve Huh7.5.1 cells.
BMS=BMS-200150. D, Treatment of infected cells for 5 hours does not inhibit intracellular
HCV replication. Protein lysates were harvested from cultures described in panel B and
equal amounts of total protein were blotted for NS5A. The positions of HCV NS5A and
loading control GAPDH are indicated. D is the DMSO control, 40, 80, and 120 are the doses
of silymarin in μM, and BMS is the MTP inhibitor BMS-200150. E, Silymarin blocks apoB
secretion from primary human hepatocytes. Cells were treated with the indicated
concentrations of SM for 24 hours before supernatants were harvested and apoB measured
by ELISA. F, Silymarin blocks apoB secretion in HepG2 cells. Cells were treated with the
indicated μM concentrations of silymarin for 5 hours before supernatants were harvested and
apoB measured by ELISA. Inset, Silymarin blocks intracellular apoB levels. Cell lysates
from HepG2 cells treated in panel F were probed for apoB by western blot. apoB100 and
loading control GAPDH are indicated with arrows. M is the media control, D is the DMSO
control, and 40, 80, and 120 are the doses of silymarin in μM.
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Figure 5. Silymarin inhibits total virus transmission and cell-to-cell spread
Naïve unlabelled Huh-7.5 cell targets were pre-incubated with 80μM Silymarin or
equivalent volume of DMSO for 1h at 37C. The pre-treated cells were then co-cultured with
CMFDA labeled H77/JFH infected Huh-7.5 producers for 48hrs. The cultures were
performed in the presence of either mAb 9/27, an anti-E2 (HVR) neutralizing antibody or an
anti-HIV gp120 irrelevant control, mAb 10/76B. Each treatment was performed in duplicate.
The co-cultures were harvested, stained and analysed by flow cytometry and the percentage
of infected cells was calculated. Cell culture media from each co-culture was tested for the
presence of HCVcc particles. Released H77/JFH virus were readily detectably in media
containing control antibody, no infectious particles were detected in the media containing
mAb 9/27, indicating that extracellular spread of virus was not occuring and only cell-cell
spread was operative. A, Silymarin (SM) reduces both total and cell:cell transmission. B,
Silymarin inhibits both total and cell:cell transmission in comparable manner suggesting that
it does not discriminate between the alternative routes.
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